Drug-inducible systems allow modulation of the duration and intensity of cytokine expression in liver immuno-based gene therapy protocols. However, the biological activity of the transgene may influence their function. We have analyzed the kinetics of interleukin-12 (IL-12) expression controlled by the doxycycline (Dox)-and the mifepristone (Mif)-dependent systems using two long-term expressing vectors directed to liver: a plasmid administered by hydrodynamic injection and a high-capacity adenoviral vector. Daily administration of Dox or Mif was associated with a progressive loss of inducibility and a decrease of murine IL-12 production. This inhibition occurred at the transcriptional level and was probably caused by an interferon (IFN)-g-mediated downmodulation of liverspecific promoters that control the expression of transactivators in these systems. Genome-wide expression microarrays studies revealed a parallel downregulation of liverspecific genes in mice overexpressing murine IL-12. However, a promoter naturally induced by IL-12 was also inhibited by this cytokine when placed in a plasmid vector. Interestingly, treatment with sodium butyrate, a class I/II histone deacetylase inhibitor, was able to rescue liverspecific promoter activity solely in the vector. We conclude that biologically active IL-12 can transiently inhibit the function of drug-inducible systems in non-integrative DNA vectors by reducing promoter activity, probably through IFN-g and protein deacetylation-dependent mechanisms.
Introduction
The success of gene therapy depends on reaching adequate levels and duration of transgene expression in a target organ or tissue. When the therapeutic gene is toxic, this requirement needs to be coupled with an efficient gene regulatory system. However, the biological effects of the gene product in the organism may affect its own regulation in vivo through mechanisms that are difficult to predict in vitro. This is especially relevant in case of molecules with immunostimulating properties that have been successfully used in cancer gene therapy.
Interleukin-12 (IL-12), a potent inducer of interferon (IFN)-g, has been shown to exert efficient antitumor effects against liver cancer. A strategy based on the intratumor (i.t.) injection of an IL-12-expressing adenoviral vector (Ad-CMVmIL12) resulted in low toxicity, tumor reduction and prolonged survival in different animal models of metastatic and primary liver cancer (reviewed in Prieto et al.
1
). However, a limited and transient antitumor effect was evidenced with a similar approach using Ad-CMVhIL-12 vector in a Phase I clinical trial, probably due to low levels and short-term expression of the transgene. 2, 3 This prompted the development of new vectors and a strategy based on the long-term expression of IL-12 in the liver. To avoid toxicity of the cytokine, we placed the two IL-12 chains under the control of the doxycycline (Dox)-or the mifepristone (Mif)-inducible systems. 4, 5 This allows modulation of IL-12 expression in a dose-and timedependent manner upon administration of the inducer drug (Dox or Mif), as reported for hGH and IFN-a in a similar setting. 6, 7 Here we study the influence of the biological effect of IL-12 on the in vivo function of these systems. In our study, the production of IL-12 is restricted to the liver by placing transactivators (TAs) under the control of tissue-specific promoters, and also by virtue of the vectors and delivery methods used. In the case of the Dox-inducible system, the plasmid pTonT(L2)-IL12 was administered by hydrodynamic (HD) injection in mice, 4 whereas the Mif-inducible system was delivered by intravenous or intrahepatic injection on a high-capacity adenoviral vector (GL-Ad/ RU-IL-12). 5 In each case, two sets of vectors were constructed to express either human IL-12 (hIL-12) or murine . In mice, hIL-12 is not biologically active and was used as a reporter gene whose production can be easily quantified in the serum of animals. Here we describe the kinetics of mIL-12 expression induced from the pTonT(L2)-mIL12 plasmid and the viral vector GL-Ad/RUmIL-12 in the liver of immunocompetent mice. The results evidence a drastic although reversible silencing of mIL-12 expression following continuous transgene induction. In contrast, the expression of hIL-12 was more stable using these same systems, as reported previously. 4, 5 We have also defined the effect of mIL-12 on endogenous liver-specific gene expression, and the participation of IFN-g at least in the initial stages of transgene inhibition on plasmid-and adenoviralbased vectors. Finally, we describe that the histone deacetylase inhibitor (HDACi) sodium butyrate (NaB) is able to alleviate transgene silencing in vivo.
Results

Kinetics of IL-12 production using drug-dependent gene regulatory systems in mice
To study the influence of transgene expression on the function of inducible systems in vivo, we have used the immunostimulatory cytokine mIL-12 in the context of a Tet-on system (plasmid pTonL2(T)mIL12) or an Mifinducible system (adenoviral vector Ad-GL/RUmIL-12). As a control, we used identical vectors expressing hIL-12, which is not biologically active in mice (pTonL2(T)-hIL12 and Ad-GL/RUhIL-12). Schematic representations of the plasmids and the adenoviral vector genomes are shown in Figures 1a and b , respectively. The plasmid pTonL2(T)-hIL12 was administered to C57BL/6 mice by HD injection and hIL-12 induction was carried out by administration of Dox for eight consecutive days. The concentration of hIL-12 in the serum of animals was measured at different time points by enzyme-linked immunosorbent assay. In the absence of Dox, no hIL-12 was detected (data not shown). As expected, the continuous induction stimulated sustained levels of hIL-12, with only a moderate reduction at day 8 versus day 1 (Figure 1c) . In contrast, when the same procedure was carried out with the pTonL2(T)mIL12 plasmid in a 10-day-induction protocol, a progressive reduction of mIL-12 was observed starting at day 3, with more than 100-fold decrease at days 8 and 10 ( Figure 1e ). Interestingly, when the same induction protocol was repeated after a resting period of 3 weeks, inducibility was restored ( Figure 1e , dark columns) and expression of mIL-12 followed the same pattern of progressive decline observed in the first round. Apart form a moderate s -M2 DNA-binding site. Palb: minimum albumin promoter; ITR: inverted terminal repeat; C: adenoviral packaging signal; HPRT and C346: stuffer DNA derived from human hypoxanthine phosphoribosyl transferase locus and human cosmid C346, respectively; GAL4BS: GLp65 DNA-binding site; E1b-TATA: adenoviral E1b minimal promoter. (c) pTonL2(T)-hIL12 (50 mg) was administered to C57BL/6J mice (n ¼ 5) by hydrodynamics injection followed by 8-day-induction period with Dox. (d) GL-Ad/RU-hIL-12 (3 Â 10 9 IU) was administered to C57BL/6J mice (n ¼ 5) by i.v. injection and Mif was administrated for 10 days intraperitoneally. (e) pTonL2(T)-mIL12 (50 mg) was injected into BALB/c mice (n ¼ 5), and Dox was administrated in two rounds separated by a 3-week resting period. (f) GL-Ad/RU-mIL12 (2.5 Â 10 8 IU) was inoculated to C57BL/6J mice (n ¼ 4) followed by two rounds of Mif administration separated by a 10-day resting period. IL-12 was measured on serum samples at the indicated time points. IL-12, interleukin-12; i.v., intravenous; Mif, mifepristone; TTR, transthyretin promoter.
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M Reboredo et al reduction in mIL-12 levels, the kinetics of both rounds of induction were identical. Similar experiments were performed with the viral vector carrying the Mifinducible system. Ad-GL/RUhIL-12 or Ad-GL/RUmIL-12 was administered intravenously by tail vein injection and IL-12 induction started 2 weeks later by daily intraperitoneal (i.p.) injections of Mif. Serum IL-12 was measured 10 h after drug administration. As shown in Figure 1d , the inducibility was maintained in mice inoculated with Ad-GL/RUhIL-12, as reported previously. 5 However, as observed with the plasmid vector, progressive silencing of mIL-12 expression occurred (Figure 1f ). Again, a short period without induction (in this case of 10 days) was sufficient to recover the function of the system almost completely (Figure 1f , dark columns). These results indicate that the biological activity of a transgene product such as IL-12 can inhibit the function of a drug-inducible system. This effect seems to be independent of the regulatory system and the type of vector used. The recovery of inducibility after a resting period argues against the loss of transgene as the explanation for this phenomenon. In fact, measurement of vector DNA by real-time PCR after eight daily inductions did not reveal a significant reduction compared with the first day of induction (data not shown).
Inhibition of IL-12 expression is associated with TA downregulation
To study the mechanism of mIL-12 reduction, we analyzed if the amount of protein detected in serum was associated with a parallel decrease of mRNA. To this end, we killed animals that had been treated with pTonL2(T)mIL12 or Ad-GL/RUmIL-12 at the beginning or the end of the induction protocol, and quantified the amount of mIL-12 mRNA in the liver. As shown in Figures 2a and b , continuous induction caused a drastic (40-fold) reduction of mIL-12 mRNA independently of the vector used. We next explored whether the system was inhibited at the level of TA production, since transcription of mIL-12 is controlled by inducible promoters that respond to rtTA2 S -M2 or GLp65 in the Dox-and Mif-dependent systems, respectively, and there is a direct correlation between TA levels and transgene induction. 4 To this end, we quantified rtTA2 S -M2 and GLp65 mRNAs in the same liver samples used above. We observed 20-fold decreased expression of both TAs, which was consistent with the reduction of mIL-12 levels (Figures 2c and d) . In contrast, a similar amount of TAs and hIL-12 mRNAs was detected throughout all the induction protocol (data not shown). Interestingly, at day 1, rtTA2 S -M2 expression was enhanced about two times with Dox compared to untreated animals ( Figure 2c ). This effect was seen when Dox was given either intraperitoneally or in drinking water and also when using hIL-12 or luciferase reporter genes under the control of the Dox-inducible system (data not shown). A similar behavior was observed for Mif-treated animals ( Figure 2d ). These observations suggest that although Dox and Mif can induce TA expression by themselves, this induction cannot alleviate the repression effect of mIL-12 on gene transcription after several days of drug administration. Together, our data indicate that mIL-12 induces reduction of rtTA2 S -M2 and GLp65 mRNA levels, and therefore a negative feedback is established causing a decrease of mIL-12 expression, unrelated to loss of vector DNA. This suggests that inhibition of TA expression could be the consequence of EalbPa1AT and transthyretin (TTR) promoter silencing, since rtTA2 S -M2 and GLp65 are driven by these liver-specific promoters in the Dox-and Mif-dependent systems, respectively (Figures 1a and b) . To obtain a general perspective about the influence of IL-12 on liver-specific promoters, we performed gene expression microarray analysis to identify genes that are differentially expressed in response to this cytokine. To this end, mice were injected with the pTonL2(T)-mIL12 or control plasmid EalbPa1AT-rtTA2, 4 in which the TA is expressed but no IL-12 cassette is present. Both groups were treated with Dox for three consecutive days, and then liver samples were collected for RNA extraction and analysis. A total of 2030 genes-probesets (with FDR (false discovery rate) ¼ 0.05) were found altered when mIL-12 was induced. Among them, a number of IFN-g responsive genes such as Icsbp1, Ifi47, Ifi203, Iigp1, Irf1, Stat1 and IFN-g itself were upregulated (Figure 3a ). Since activation of IFN-g is a hallmark of IL-12 function in vivo, 8 this observation demonstrates the biological activity of the transgene and the functional relevance of the results found using the genome-wide expression microarrays. We next focused on a set of 101 liverspecific genes selected based on a 200-fold higher expression in murine liver compared with other tissues, according to the transcriptomic profiles in Gene Expression Atlas (http://symatlas.gnf.org/SymAtlas/). 9 We searched for these liver-specific genes in the microarrays and found a set of 94 gene probesets, which were used to perform a hierarchical cluster analysis. The resulting gene expression profiles along the six sample microarrays are presented as a heatmap (Figure 3b ). It shows a clear differential expression between the samples in Figure 3 Effect of IL-12 on endogenous gene expression. Plasmids pTonL2(T)-mIL-12 or Ealba1AT-rtTA2 S -M2 (carrying only the transactivator gene) were injected into BALB/c mice (n ¼ 3) and Dox was administered i.p. during 3 days before killing. Liver samples of both groups of animals were used for microarray analysis. (a) The normalized expression signal of eight genes in untreated (TAd, gray columns) or IL-12-treated animals (TAdIL, black columns) is represented: interferon-g (IFN-g), interferon-g inducible protein 47 (Ifi47), interferonactivated gene 203 (Ifi203), interferon-inducible GTPase 1 (Iigp1), interferon regulatory factor 8 (Irf8, also called Icsbp1), signal transducer and activator of transcription 1 (Stat1), interferon regulatory factor 1 (Irf1). Gapdh signal was included as a control reference gene that does not change. The normalized expression signal corresponds to the average of ratios of log 2 expression signals. The standard error for the three samples is also indicated. In this way, a relative increment of 1.1 and 1.6 (in the log 2 ratio scale) corresponds to a 2.15-and 3.0-fold induction (in the lineal ratio scale), respectively. (b) Heatmap of the hierarchical cluster analysis of a set of the 94 liver-specific gene-probesets selected. Indicated are the downregulated (green) and upregulated (red) genes in samples where mIL12 was induced (TAdIL 1, 2 and 3) and the ones that were not (TAd 1, 2 and 3). Arrows points the probesets corresponding to relevant genes. (c-f) Differential expression of a subset of liverspecific genes (albumin, a-1 antitrypsin, transthyretin and hemopexin) in mice (n ¼ 5) injected with pTonL2(T)-mIL-12 or pTonL2(T)-hIL-12 and treated for 8 days with Dox. Real-time RT-PCR was performed to determine mRNA content in the liver. *Significant differences (*Po0.05, **Po0.01). Gapdh, glyceraldehyde-3-phosphate dehydrogenase; IL-12, interleukin-12; i.p., intraperitoneal; RT, reverse transcriptase.
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M Reboredo et al which mIL12 was induced (TAdIL 1, 2 and 3) and the ones that remained in the basal state (TAd 1, 2 and 3). These sets of genes present a mean difference in the expression of 0.35 (in log 2) between the two states. Among the genes repressed in the presence of mIL-12 we found albumin (Alb1), a-1antitrypsin (also called Serpina1a) and transthyretin ( Figure 3b ). This is important because analogous promoters and/or enhancers of these genes were included in the Dox-and Mif-dependent gene inducible systems to direct TA expression ( Figures  1a and b) . To confirm these data, we performed an independent experiment in which the plasmids pTonL2(T)-mIL12 or pTonL2(T)-hIL12 were administered by HD injection and induction was carried out for 8 days.
At this time, mRNA corresponding to these genes was quantified from the liver of mice by real-time RT-PCR.
No differences in albumin, a-1antitrypsin and TTR mRNA levels were found in animals expressing hIL-12 compared with untreated controls (data not shown). In contrast, mIL-12 caused a 3-to 8-fold reduction in the expression of these liver-specific genes (Figures 3c-e) .
The results indicate that the biologically active mIL-12 causes a significant repression of endogenous liverspecific promoters that are relevant for the function of our inducible systems. On the other hand, a number of genes like hemopexin (Hpxn) were upregulated in response to mIL-12 expression, as revealed in the microarray analysis (Figure 3b) , and confirmed by realtime RT-PCR ( Figure 3f ).
An IL-12-inducible promoter does not alleviate transgene silencing
To analyze the direct influence of mIL-12 on the promoters used to control TA expression, we used a plasmid carrying the hAAT gene driven by the EalbPa1AT promoter (EalbPa1AT-hAAT). 10 Human AAT is a good reporter protein in Balb/c mice and can be easily monitored in serum by enzyme-linked immunosorbent assay, unlike intracellular TA proteins. EalbPa1AT-hAAT plasmid was co-administered with either pTonL2(T)-mIL12 or pTonL2(T)hIL12 by HD injection. As expected, activation of mIL-12 expression by Dox caused marked decrease in hAAT levels after 8 days of induction, whereas no effect was observed with hIL12 ( Figure 4a ). The same result was observed using a plasmid containing the TTR promoter driving the expression of hAAT (data not shown). This result initially suggested that mIL-12 exerts the same influence on endogenous promoters as well as those located in extrachromosomal plasmids. If this were a general feature, we would expect that the promoters of genes upregulated by mIL-12, such as hemopexin, could be used to drive the expression of TAs and avoid mIL-12-mediated downregulation in the inducible system. In addition, the hemopexin promoter IL-12 mediates inhibition of inducible systems M Reboredo et al seems a good candidate because it was shown to respond to IL-6-mediated inflammation signals 11 and to drive stable transgene expression if combined with an EII HBV liver-specific enhancer. 10 To test this strategy, we repeated the experiment described in Figure 4a using the EIIPHpx-hAAT plasmid instead of EalbPa1AT-hAAT. Surprisingly, we found downregulation of hAAT expression in response to mIL-12 induction (Figure 4b ), which could indicate dissociation between the effect on the endogenous and the extrachromosomal vector-derived promoter.
Involvement of IFN-g in the inhibitory effect of IL-12 on gene expression IL-12 stimulates the production of IFN-g in different cell types, and this mediates many of the biological effects of this cytokine. To define whether the inhibition of liverspecific gene regulatory systems was a direct effect of IL-12 on transduced hepatocytes, or if it was mediated by IFN-g, we analyzed the presence of IL-12 and IFN-g receptors in murine hepatocytes. The expression of IL-12 receptor b1 and b2 chains and IFN-g receptor a and b chains were quantified in total mRNA samples isolated from primary murine hepatocytes, whole-liver samples and from the well-differentiated murine hepatocellular carcinoma cell line Hepa1-6. Both receptor subunits need to be present in the same cell for efficient signal transduction. 12 We found that only the b2 chain of IL-12 receptor is expressed in hepatocytes and in Hepa1-6 cells (Figures 5a and b) , indicating that these cells are not able to transmit IL-12-mediated signals. The detection of both chains in whole-liver samples (Figures 5a and b) may be due to the presence of non-parenchymal cells such as T lymphocytes and natural killer cells. On the other hand, as previously described for most somatic cells, 13 a functional IFN-g receptor is also present in liver, hepatocytes and Hepa1-6 cells (Figures 5c and d) . Since IL-12 can activate T and natural killer cells to produce IFN-g, and this cytokine is abundantly secreted in IL-12-stimulated organisms, 14 ) that received the Ad-GL/RUmIL-12 vector and were subjected to seven daily inductions of mIL-12 with Mif. In contrast to wt mice, sustained expression of mIL-12 was observed in the IFN-g-R knockout mice during all the induction period despite the high levels of IFN-g detected in both types of animals (Figures 6a and  b) . This indicates an important role of IFN-g signaling in the downregulation of liver-specific drug-inducible systems. To investigate if this effect could be attributed to the immunostimulatory functions of IFN-g, we studied if silencing takes place in severely immunosuppressed animals like nod/severe-combined immunodeficiency (SCID) mice. As shown in Figure 6 , a parallel decline in mIL-12 expression in wt and nod/SCID mice was observed, indicating that transgene silencing does not require an efficient immune system but only the ability of lymphoid cells to produce IFN-g in response to IL-12, and the expression of IFN-g receptors.
NaB can rescue mIL-12 silencing without affecting IFN-g signaling Histone deacetylase inhibitors induce euchromatin conformation and can revert gene silencing in a variety of circumstances. 15 It has been reported that HDACi can increase the expression of endogenous 16 as well as extrachromosomal transgenes in vitro and in vivo. 17 Therefore, we studied if NaB, a commonly used HDACi, was able to restore mIL-12 expression when induced from the pTon(L2)-mIL12 vector. The plasmid was administered to mice as described previously, and induction of mIL-12 with Dox was carried out for 8 days in the presence or absence of NaB treatment at 1.25 or 2 g kg
À1
. As shown in Figure 7a , NaB partially avoided the reduction of mIL-12 production in a dose-dependent manner. Animals treated with 2 g kg À1 NaB achieved 10 times higher cytokine levels as compared with untreated 
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M Reboredo et al mice at the end of the induction period. This dose of NaB has been described to be sufficient to recover the acetylation status of histones in mice, and is not associated with toxic effects. 18, 19 Following NaB treatment, the mIL-12 concentration in serum correlated with an increase in rtTA2 S -M2 and mIL12 mRNAs in the liver of mice measured at day 8 ( Figure 7b ). To determine whether NaB was not only protecting the promoters present in vector DNA, but also the corresponding endogenous liver-specific promoters, we measured the expression of albumin, a-1 antitrypsin and TTR in the same liver samples. We did not see any difference in the expression of these three genes in treated and untreated animals, indicating that NaB is not able to prevent mIL-12-mediated endogenous gene downregulation in mice (Figure 7b ). These data suggest that the mechanisms responsible for vector promoter silencing may be different from the ones affecting the cellular genome. Since IFN-g can induce transgene downregulation 20 ( Figure 6a) , and some HDACi suppress synthesis of various cytokines, including IFN-g, 21, 22 we investigated whether the protective role of NaB was due to a blockade of IFN-g-signaling pathways in our assay conditions. To this end, we measured the expression of the downstream genes Stat1 and Ifit2 in the liver of mice that received the pTon(L2)-mIL12 plasmid and were given Dox for 8 days in the presence or absence of NaB. As a negative control for IFN-g pathway activation, we included IFN-g-R knockout mice overexpressing murine IL-12. As expected, the expression of Stat1 and Ifit2 was increased in response to mIL-12 in wt but not in IFN-g-R knockout mice (Figure 7c ). NaB caused no variation in either the basal or the mIL-12-induced expression of Stat1 and Ifit2 (Figure 7c) , and similar amount of IFN-g was detected in the serum of NaB-treated and -untreated mice (data not shown). These data indicate the lack of an obvious interference of NaB on IFN-g production and signaling.
Discussion
The ability to exogenously modulate the intensity and duration of transgene expression is essential when placing transgenes with toxic potential in long-expressing vectors. The use of drug-inducible systems would allow the design of tailored protocols adapted to the disease and the status of the patient. In the case of IL-12, these features are critical and may determine the safety and efficacy of the treatment because this cytokine causes severe toxicity at high doses. In this study, we have characterized the in vivo performance of drug-inducible systems based on hepato-specific promoters for the regulation of IL-12 expression within the liver. We provide evidence that the biological activity of IL-12 causes a gradual inhibition of these systems. Their ability to induce transgene expression is reduced after 3 days of drug administration, and it virtually disappears after an 8-to 10-day-induction period. This phenomenon occurs with both regulatory systems tested in the present work, the Tet-on and Mif-dependent systems, and is not related to the vector (naked DNA or high-capacity adenoviral vector) or delivery method used (HD-based injection or intravenous and intrahepatic liver transduction). It also seems to be independent of the strain of mice analyzed, because we observed the same effect in C57BL/6J and Balb/c (Figure 1) , as well as in 129S2/SvHsd mice (manuscript in preparation). Interestingly, the silencing of gene expression is not an intrinsic limitation of these regulatory systems, since continuous activation of gene expression can be maintained with other transgenes, like human IL-12 and luciferase, that do not elicit the biological effects of murine IL-12 in mice. [4] [5] [6] This indicates that potential problems regarding the pharmacokinetics of inducer drugs (Dox and Mif) can be discarded.
Due to the complex functions of IL-12 in vivo, a number of different mechanisms may account for the rapid silencing of gene expression observed. We have ruled out the possibility that it is due to the elimination of transduced cells, since no specific decrease of transgene content was observed in the liver of induced mice (data not shown). This is in agreement with the ability of the systems to recover maximum inducibility after a resting (drug free) period of at least 5 days ( Figure  1 and our unpublished data) . The blockade of IL-12 production was at the level of transcription, because a parallel reduction of its mRNA was observed. The mechanism involves a downregulation of both Doxand Mif-associated TA gene expression (rtTA2 s -M2 and GLp65, respectively), suggesting an inhibition of the liver-specific chimeric promoters that were used to control the expression of these TA in our systems. 4, 5 The promoters were constructed by combining regula- IL-12 mediates inhibition of inducible systems M Reboredo et al tory sequences from the mouse albumin, human a-1 antitrypsin and mouse TTR genes, which allow sustainable and high levels of reporter gene expression in mice. 6, 10 Interestingly, gene expression microarray analysis (together with real-time RT-PCR validations) indicated that endogenous expression of albumin, a-1 antitrypsin and TTR was inhibited in animals overexpressing IL-12, which is consistent with changes observed in acute-phase response. 23, 24 Therefore, it was possible that these elements were also inhibited in the expression cassettes introduced in our vectors. However, although the endogenous expression of hemopexin was increased in response to IL-12, the hemopexin promoter was equally downregulated by IL-12 when placed in a plasmid vector to control hAAT reporter gene expression. This indicates that IL-12 may influence differently the transcriptional activity of regulatory sequences depending on their localization: chromosomic or extrachromosomic. Therefore, we believe that the performance of tissue-specific promoters in gene therapy vectors is difficult to predict just on the basis of endogenous gene expression profiles. À/À mice expressing IL-12 are included as negative control for IFN-g pathway activation. *Significant differences (Po0.05). ns, nonsignificant differences (P>0.05). IL-12, interleukin-12; IFN-g, interferon; NaB, sodium butyrate; wt, wild type.
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The choice of vectors and the design of expression cassettes used in the present study ensure the synthesis of IL-12 in hepatocytes, but the cytokine is rapidly secreted to the circulation, where it can reach specific receptors present in the surface of target cells such as T lymphocytes and natural killer cells. When activated, these cells will secrete IFN-g. 8 On the basis of our observation that murine hepatocytes do not express functional receptors for IL-12, the silencing of gene expression must be mediated by an indirect mechanism, most probably related to the activation of the IFN-g pathway. This concept is supported by our finding that in knockout mice for the IFN-g receptor, the system does not suffer the loss of inducibility observed in wt animals. IFN-g plays a pivotal role in the development of adaptive immune responses and antitumor activity mediated by IL-12; however, it could diminish gene therapy efficacy through transgene silencing. This is in agreement with previous observations from other groups using plasmid, adenoviral and retroviral vectors in vitro and in vivo. 20, 25, 26 In any case, it is worthwhile to stress that this is a reversible transcriptional inhibition, and gene expression can be recovered after a cytokine-free resting period. In addition, we describe here that silencing takes place in animals with severely impaired immune system, such as nod/SCID mice. Together, these data indicate that transcriptional inhibition mediated by IFN-g in hepatocytes is responsible for this phenomenon, independently of the immunological effects of this molecule.
Gene expression can be regulated through chromatin remodeling mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). This is a dynamic process that can be affected by structurally diverse HDACi, including NaB. 15, 27 Here we describe that NaB treatment alleviates transgene silencing in vivo in our assay conditions. This is consistent with the recent observation of episomal vector chromatinization in the liver of transfected mice. 28 Enhanced expression of transgenes upon treatment with NaB was previously observed by other groups using adenoviral vectors 29 and naked DNA. 17, 30 However, the mechanism responsible for this phenomenon is difficult to access, since HDACi affects a number of cellular proteins besides histones. 15 The ability of IFN-g to decrease histone acetylation through activation of HDACs or inhibition of HATs has been described in different systems, 31, 32 and is believed to be relevant for its biological functions. 33, 34 We observed protection from transgene silencing by NaB without major disruption of IFN-g pathways such as those leading to Stat1 and Ifit2 induction. Thus, it could re-activate transgene expression by unraveling chromatin at relevant vector promoter sequences, by activating transcription factors or by any of the numerous alternative mechanisms defined for HDACi. 15, 27 Interestingly, the effect of NaB was predominant on extrachromosomal DNA, since no re-activation of endogenous liver-specific promoters was observed. Although the mechanism is not clear at this moment, the development of methods to counteract IL-12 transgene silencing is relevant because maintenance of sustained levels of this cytokine for a defined period of time may be necessary to achieve an optimal therapeutic response. The use of HDACis as adjuvants in the induction regime would be possible in humans, since several of these agents are being investigated as anticancer agents in clinical trials. 27 Moreover, some HDACis have shown to greatly stimulate standard chemotherapy and gene therapy strategies against liver cancer in experimental models. 35, 36 In summary, we describe here that Dox-and Mifdependent regulatory systems suffer a rapid loss of inducibility when they express biologically active IL-12. The inhibition is transient, is mediated by IFN-g and is partially blocked by HDACis. These observations have relevance for the design of gene therapy strategies involving controlled expression of immunostimulatory cytokines for the treatment of cancer and other diseases.
Materials and methods
Animal manipulation
Five-to six-week-old female C57BL/6J and BALB/c mice were purchased from Harlan Laboratories (Barcelona, Spain). Nod/SCID mice (NOD.CB17-Prkdc scid/J) were obtained from Jackson Laboratory (Charles River, Barcelona, Spain). IFN-g receptor-deficient mice (IFN-g R À/À ) were provided by Dr Gonzalez-Aseguinolaza. 37 Animals were maintained under standard conditions and all procedures were approved by the Institutional Ethical Committee. Each plasmid DNA (50 mg) re-suspended in 2 ml of saline (NaCl 0.9%) was injected into mice using the HD-based procedure. 38 The viral vector was administered by tail vein injection diluted in 200 ml of saline or by intrahepatic injection in 50 ml to increase transduction efficacy. Direct hepatic injection was performed following laparotomy, as described. 39 In the case of the Tet-on system, inductions started 1 week after plasmid injection. Doxycycline (Sigma, St Louis, MO, USA) was given in drinking water (2 mg ml À1 with 5% sucrose) or by i.p. injection (50 mg g
À1
). In the case of the Mif-inducible system, Mif (Sigma) was administered by i.p. injection starting 2 weeks after the vector administration at a dose of 250 mg kg À1 dissolved in 60 ml of sesame oil. NaB (Sigma) was daily administered intraperitoneally at 1.25 or 2 g kg À1 after the second day of induction. Blood samples were obtained by retro-orbital bleeding under inhalatory anesthesia (isoflurane, Forane Abbott Laboratories, Madrid, Spain). When Dox or Mif were administered intraperitoneally, blood was collected after 10 h. When Dox was given orally, blood was taken in the morning. Serum was recovered by double centrifugation at 10 000 r.p.m. for 5 min and stored at À20 1C until protein measurement.
Vectors
The pTonL2(T)-hIL12 and pTonL2(T)-mIL12 plasmids were generated as described. 4 In both constructs the EalbPa1AT promoter directs the expression of the Doxresponsive TA rtTA2 S -M2. GL-Ad/RU-mIL12 adenoviral vector carries the Mif-responsive TA (GLp65) under the control of the liver-specific TTR promoter 6 and was generated as reported. 5 The p35 and p40 of IL12 are linked by internal ribosomal entry site (IRES). Plasmids EalbPa1AT-hAAT and EIIPHpx-hAAT express the human a1-antitrypsin (AAT) gene under the control of liver-specific promoters described previously. 10 Plasmid DNA was purified from bacteria using Endofree Plasmid Maxi Kit (Qiagen, Santa Clara, CA, USA) and stored in Tris-EDTA (TE 10:1) buffer solution at À20 1C. HC-Ad IL-12 mediates inhibition of inducible systems M Reboredo et al vector stocks were prepared and stored as described earlier. 5 
Hepatocyte isolation
The liver of an 8-week-old female C57BL/6J mouse was perfused with collagenase solution (Sigma) and hepatocytes were isolated as described. 40 Cells were stored at À80 1C before analysis.
Determination of IL-12, IFN-g and AAT levels
Serum concentration of IL-12 and IFN-g were determined by OptE1A human IL-12 (p70), OptE1A mouse IL-12 (p70) and mouse IFN-g enzyme-linked immunosorbent assay kits (BD Bioscience PharMingen, San Diego, CA, USA). Serum levels of AAT were measured by enzyme-linked immunosorbent assay as described previously. 10 RNA isolation, DNA extraction and RT-PCR After killing, liver samples were harvested, rapidly frozen in liquid nitrogen and stored at À80 1C. Total RNA was extracted with TRIzol Reagent (Invitrogen, Paisley, Scotland, UK) from a portion of liver (10 mg) homogenized with an Ultraturrax Driver T.25 (Janke & Kunkel, Ika-Labortechnik, Germany), following the manufacturer's protocol. The RNA was stored at À80 1C before further processing. Genomic DNA was eliminated from the samples by DNase I (Invitrogen) treatment using 1 ml/mg RNA. Total cDNA was generated using 2 mg RNA in 50 ml mix containing 0.8 mM dNTP mix, 5.3 mM p(dN) 6 random primers (Roche, Mannheim, Germany), 4 mM dTT (Invitrogen), 48 U of RNase inhibitor (Invitrogen), 240 U of M-MLV RT (Invitrogen) and 10 ml of buffer provided by the supplier. The tubes were incubated at 37 1C for 1 h and 95 1C for 1 min.
Quantitative PCR
cDNA was quantified using the iQ SYBR green Supermix using an iQ5 system from Bio-Rad (Hercules, CA, USA). We designed all primers (Table 1) Immediately following PCR, a melting curve was undertaken by raising the incubation temperature from 55 to 95 1C to confirm amplification specificity. For the same purpose, we also performed electrophoresis of the final PCR product. Annealing temperature is 60 1C for all the set of oligos except for AAT (Serpina1), which was performed at 58.5 1C, Stat1 at 62 1C and Il12rb2 at 58 1C. Detection temperature was 79 1C for IRES, GLp65, Ifit2 and albumin DNA, and 82 1C for all the rest. Samples were run in duplicate and mRNA levels were normalized using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control. The amount of each transcript was indicated by the formula: 2 C t ðGAPDHÞÀC t ðgeneÞ , C t being the point at which the fluorescence rises appreciably above background.
Microarray data analysis: normalization, signal calculation, significant differential expression and sample/gene profiles clustering We used GeneChip Mouse Genome 430A 2.0 Array (Affymetrix) representing approximately 14 000 wellcharacterized mouse genes. Microarray data analysis was performed using the following strategy and methods. Robust multichip average (RMA) algorithm Table 1 Primers used in this study was used for background correction, intra-and intermicroarray normalization and expression-signal calculation. 41, 42 Once the absolute expression signal for each gene (that is, the signal value for each gene probeset) was calculated for the whole microarray set, significance analysis of microarrays (SAM) algorithm 43 was applied to calculate significant differential expression and to find the gene probesets that changed in each type of samples. The method uses permutations to provide robust statistical inference of the most significant probesets and provides P-values adjusted to multiple testing using FDR. 44 The cutoff of adjusted P-values applied to select significant genes was o0.05. After identification of the differentially expressed gene probesets, the corresponding matrix of expression values for the microarray samples studied was analyzed using the 'hclust' clustering algorithm. 45 This algorithm performs agglomerative hierarchical cluster analysis with complete linkage to find similarity between gene probesets based on their similar gene expression profiles along the analyzed microarray samples. We applied these methods using R and Bioconductor as main computational and bioinformatic tools (www.bioconductor.org). R is a programming language and software environment for statistical computing (www.r-project.org). The normalized expression signals calculated for the genes in Figure 3a correspond to the average of ratios of log 2 expression signals. The ratios were obtained dividing the log 2 signal of each gene in each sample by its median expression value along the six mice samples. In this way, the controls are close to 1 (that indicates no-change) and the changes in log 2 scale are comparable for the different genes.
Statistical analysis
Data were analyzed by Mann-Whitney nonparametric tests. We used nonparametric statistics because sample size was less than 10.
